With the broader market cracking under rising yields, oil prices and Fed hike fears, most macro-driven trades are already crowded — but Eli Lilly has a company-specific catalyst this week with its obesity pipeline update, a franchise investors care deeply

Verdict: The fundamentals argue for LLY, the mechanical record argues against — wait for the catalyst

Lilly's business case is genuinely strong: Q2 2026 revenue grew 16.0% quarter over quarter to $23.0B, gross margin expanded 3.8 points to 85.8%, and operating cash flow doubled to $10.7B, with the dividend compounding at roughly 15.3% a year. But the trade's mechanical expression is the problem — the attached rule set lost money in every tested window, returning -16.9% over 60 months (440 trades, 47.0% win rate) and -4.2% even in the best recent 12-month window. The freshest cracks matter too: net margin fell from 37.4% to 30.9% and debt-to-equity jumped from 1.39 to 1.62 in the latest quarter, while the mid-2026 ownership filing (whose coverage deadline has passed) showed roughly $2.9M of net insider open-market selling rather than current alignment. The strongest point for the trade is the obesity pipeline catalyst this week, which per the idea can move the stock independent of macro. The strongest point against is a realized negative track record at every horizon combined with an early-exit trigger sitting essentially at the current price of $1,183.46 versus the $1,182.73 resistance level. A positive efficacy readout this week followed by insider buying in the next ownership filing would flip the verdict toward taking the long.

Trade now: LLY long setup is fully triggered — here's the exact entry math

**LLY is a live entry, not a waiting game.** Every entry condition is met as of the latest daily close: price is above zero at $1,183.46, RSI (14) is 63.7 (needs above 20), ADX (14) is 44.1 (needs above 20), and price sits $19.96 above the first support level at $1,163.5. If you are following this rules-based long, today's plan is to enter at or near the close, sized to the fixed-risk method at roughly 2.3% of equity risked per trade, capped at 25% of the portfolio in a single name. **Risk and reward in price terms.** The hard stop is a 2.3% adverse move, about $27.80 below entry (roughly $1,155.7), with a secondary structure stop if price closes above the second support level at $1,111.93. The take-profit sits at a 4.7% gain, about $1,238.9, above the $1,232 resistance level, and there is also an exit if price closes at or above the nearest resistance at $1,182.73 — effectively at the current price, so a small pop could trigger an early exit. Effective reward-to-risk is about 2:1. A time-based exit also closes the position after 45 trading days. **What the completed backtest actually says.** Over 60 months the strategy traded 440 times on LLY with a 47.0% win rate and returned -16.9% with a 16.96% max drawdown. The most recent 12 months are different: 78 trades, a 41.0% win rate, -4.24% return, but a shallower 7.57% max drawdown. If you take this trade, you are accepting a system whose full-history edge is negative and whose recent window is only modestly loss-making — the 2:1 trade-level ratio is the strongest part of the setup, not the long-run track record. **One setup caveat.** Parameter-sensitivity evaluation exceeded its time budget, so no robust nearby-parameter setup was established; you would be running the published parameters as-is. The idea's catalyst — the obesity pipeline update the thesis flags for this week — is the company-specific reason to act now rather than wait for a pullback toward support.

The Business Is Delivering Even If the Tape Isn't

The idea's core claim — that Lilly is an idiosyncratic long setup built on obesity pipeline demand rather than macro direction — has one major thing going for it: the fundamental engine is running hot. Second-quarter 2026 revenue came in at $23.0B, up 16.0% from $19.8B in the prior quarter, and full-year 2025 revenue growth ran at 42.5% year over year. That places Lilly in roughly the 77th percentile of Health Care peers on revenue growth, per the peer comparison across 914 companies. This is exactly the demand backdrop the thesis leans on: a franchise growing fast enough to move on its own news. Profitability supports the story too. Gross margin hit 85.8% in Q2 2026, up 3.8 points from 81.9% the quarter before and above even the strong 82.5% posted in Q4 2025. Net income was $7.1B in the quarter, and operating cash flow more than doubled quarter over quarter to $10.7B from $5.3B. A company converting that…

Scores

• Conviction score breakdown: 49
• Thesis support: 72
• Trade readiness: 45
• Risk quality: 40
• Backtest evidence: 25
• Fundamentals trend: 65

Watch items

• LLY — Obesity pipeline update (company catalyst per thesis)
• LLY — Daily close vs nearest resistance
• LLY — Daily close vs second resistance
• LLY — Unrealized P&L vs entry
• LLY — Daily close vs second support
• LLY — Net margin (Q2 2026: 30.9%)
• LLY — Insider net open-market flow
• LLY — Ex-dividend date
• LLY — ADX (14)